bioMerieux (OTCMKTS:BMXMF – Get Free Report) and Revvity (NYSE:RVTY – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations and earnings.
Profitability
This table compares bioMerieux and Revvity’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| bioMerieux | N/A | N/A | N/A |
| Revvity | 8.26% | 8.00% | 4.83% |
Earnings and Valuation
This table compares bioMerieux and Revvity”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| bioMerieux | $4.60 billion | 1.99 | $449.73 million | N/A | N/A |
| Revvity | $2.86 billion | 3.89 | $241.20 million | $2.09 | 47.68 |
bioMerieux has higher revenue and earnings than Revvity.
Risk & Volatility
bioMerieux has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500. Comparatively, Revvity has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings for bioMerieux and Revvity, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| bioMerieux | 0 | 5 | 0 | 0 | 2.00 |
| Revvity | 1 | 9 | 4 | 0 | 2.21 |
Revvity has a consensus target price of $107.73, indicating a potential upside of 8.10%. Given Revvity’s stronger consensus rating and higher probable upside, analysts clearly believe Revvity is more favorable than bioMerieux.
Institutional & Insider Ownership
86.7% of Revvity shares are held by institutional investors. 0.9% of Revvity shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Revvity beats bioMerieux on 10 of the 12 factors compared between the two stocks.
About bioMerieux
bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries. It also provides a suite of software products and services that collect, analyze, and merge various sources of data to make decisions under the BIOMÉRIEUX VISION SUITE name; designs, manufactures, and maintains instruments and software; and designs and manufactures reagents for in vitro diagnostic tests. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.
About Revvity
Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Receive News & Ratings for bioMerieux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioMerieux and related companies with MarketBeat.com's FREE daily email newsletter.
